Fri, May 9, 8:10 PM (14 days ago)
**Azenta, Inc. (AZTA) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $143.4M (Q1 2025) vs. $136.4M (Q1 2024), up 5.2%. Six months: $290.9M (2025) vs. $278.1M (2024), up 4.6%. - **Gross Profit:** $65.9M (Q1 2025) vs. $60.7M (Q1 2024), up 8.2%. Six months: $134.6M (2025) vs. $122.4M (2024), up 9.1%. - **Operating Loss:** $(16.2)M (Q1 2025) vs. $(24.2)M (Q1 2024). Six months: $(27.5)M (2025) vs. $(40.5)M (2024). - **Net Loss:** $(40.5)M (Q1 2025) vs. $(136.9)M (Q1 2024). Six months: $(53.8)M (2025) vs. $(152.6)M (2024). - **Cash & Equivalents:** $253.6M (Q1 2025) vs. $280.0M (Q4 2024). **Profit Margins:** - **Gross Margin:** 45.9% (Q1 2025) vs. 44.5% (Q1 2024). Six months: 46.3% (2025) vs. 44.0% (2024). - **Operating Margin:** -11.3% (Q1 2025) vs. -17.8% (Q1 2024). Six months: -9.5% (2025) vs. -14.5% (2024). **Cash Flow:** - **Operating Cash Flow:** $44.2M (Six months 2025) vs. $22.4M (Six months 2024). - **Investing Cash Flow:** $(61.6)M (Six months 2025) vs. $(173.0)M (Six months 2024). - **Financing Cash Flow:** $(10.3)M (Six months 2025) vs. $(185.5)M (Six months 2024). **Earnings Changes:** - **EPS (Basic):** $(0.88) (Q1 2025) vs. $(2.47) (Q1 2024). Six months: $(1.18) (2025) vs. $(2.72) (2024). **Segment Performance:** - **Sample Management Solutions:** Revenue up 7.8% (Q1 2025) and 5.2% (Six months 2025). Operating income positive at $0.6M (Q1 2025) and $2.1M (Six months 2025). - **Multiomics:** Revenue up 2.1% (Q1 2025) and 3.9% (Six months 2025). Operating loss at $(6.1)M (Q1 2025) and $(9.5)M (Six months 2025). **Trends & Uncertainties:** - **Revenue Growth:** Driven by Sample Management Solutions and Multiomics segments. - **Operational Efficiencies:** Improved gross margins due to operational efficiencies and sales mix. - **Cash Position:** Strong cash position to fund operations and capital expenditures. - **Discontinued Operations:** Sale of B Medical Systems business planned, impacting financials. **Future Operations Impact:** - **Strategic Focus:** Emphasis on core businesses post-B Medical Systems sale. - **Cost Management:** Continued cost reduction and productivity improvement initiatives. - **Market Conditions:** Potential impacts from international trade disputes and tariffs. **Key Metrics:** - **Revenue Growth:** 5.2% (Q1 2025) and 4.6% (Six months 2025). - **Gross Margin:** 45.9% (Q1 2025) and 46.3% (Six months 2025). - **Operating Loss:** $(16.2)M (Q1 2025) and $(27.5)M (Six months 2025). - **Net Loss:** $(40.5)M (Q1 2025) and $(53.8)M (Six months 2025). - **Cash Position:** $253.6M (Q1 2025). **Conclusion:** Azenta, Inc. (AZTA) shows positive revenue growth and improved gross margins, driven by operational efficiencies. However, the company faces challenges with operating and net losses, impacted by discontinued operations. The strategic focus on core businesses and cost management initiatives are crucial for future growth and stability.